Senseonics Shares Jump 26%; 2026 Sales Forecast Raised
The quarterly net loss widened from $19.5 million to $32.7 million despite approximately 140% year-over-year revenue growth.
Senseonics, which develops and sells implantable glucose monitors for people with diabetes, soared 25.71% to $12.32 in Tuesday trading, as of 9:47 AM ET, adding $133 million in market value. The gain followed Monday's earnings report and a higher annual sales outlook, announced in an SEC filing.
Higher Sales, A Wider Loss
Senseonics lifted its $62 million–$66 million forecast to $68 million–$70 million for 2026 revenue.
Third-quarter revenue: $19.6 million, up approximately 140% year-over-year; net loss: $32.7 million versus $19.5 million a year earlier.
Shares reached a new 52-week high in Tuesday trading, as of 9:47 AM ET, and were on pace for their second gain of 10% or more this month. Senseonics' market value stood at about $651 million in that session.
An Already Strong Run
Before Tuesday's jump, Senseonics shares had gained 78% year-to-date at Monday's close, against a 10% rise for the S&P 500.
The stock's run coincided with a shift in the company's sales operation: Senseonics had managed U.S. commercial operations internally for three consecutive quarters.
Its Eversense systems use an implanted sensor alongside a rechargeable, removable transmitter and a phone app for glucose readings and alerts. Eversense 365 provides monitoring for up to twelve months; Eversense E3 lasts up to six months.
Senseonics earns revenue from selling sensors and transmitters, and sometimes from procedures to insert or remove sensors. Distributors and fulfillment partners are its primary route to healthcare providers and patients.
Senseonics plans to commercially launch its Eversense 365 integration with Beta Bionics' iLet Bionic Pancreas in the fourth quarter, subject to finishing integration work and meeting applicable requirements.
Sources
- Senseonics surges 18% in premarket on Q3 beat, raised revenue outlook (SENS:NASDAQ) | Seeking Alpha — seekingalpha.com
- Senseonics: Q3 Earnings Snapshot — Associated Press
- https://www.sec.gov/Archives/edgar/data/1616543/000110465926124500/sens-ex99d1.htm — sec.gov
- Senseonics targets $68M-$70M 2026 revenue as Freedom CGM human testing begins (NASDAQ:SENS) | Seeking Alpha — seekingalpha.com
- Senseonics: Q3 Earnings Snapshot | wusa9.com — Associated Press
- The company's filing (Senseonics) — SEC filing
- Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates — Zacks Investment Research
- Senseonics — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR